Oncologia5 articoli

Impatto 2

Baseline FDG PET/CT-Defined Axillary Burden Predicts Axillary Pathologic Complete Response After Neoadjuvant Therapy in Breast Cancer.

Pubblicato: 2026-06-01

Nuklearmedizin. Nuclear medicine

MediLens Indicizzato: 2026-05-23

This study investigates predictors of axillary pathologic complete response (pCR) after neoadjuvant systemic therapy in clinically node-positive breast cancer. In a retrospective cohort of 115 patients, the rate of axillary pCR was 51.3%. The models developed showed good discrimination with AUC v...

Leggi su PubMed

Impatto 3

Fulvestrant versus capecitabine as maintenance therapy in hormone receptor-positive, HER2-negative metastatic breast cancer after first-line chemotherapy (FAMILY): a multicenter, open-label, randomized, phase 3 trial.

Pubblicato: 2026-05-22

Signal transduction and targeted therapy

MediLens Indicizzato: 2026-05-23

This study evaluates the efficacy and safety of fulvestrant versus capecitabine as maintenance therapy in hormone receptor-positive, HER-2 negative metastatic breast cancer patients after first-line chemotherapy. The trial involved 210 patients and found that fulvestrant significantly improved me...

Leggi su PubMed

Impatto 3

Aptamer Nanoswitch-Mediated Lock-Expose Mechanism Enables Highly Sensitive In Vitro Detection and Precise In Situ Membrane Imaging of HER2 Protein.

Pubblicato: 2026-05-22

ACS sensors

MediLens Indicizzato: 2026-05-23

This study presents a novel HER2-specific aptamer nanoswitch for the sensitive detection of HER2 expression in breast cancer. The sensor demonstrated a linear detection range from 10 fg/mL to 10 ng/mL and a limit of detection of 1.42 fg/mL. It successfully distinguished between healthy individual...

Leggi su PubMed

Impatto 3

Wash-Free Digital Detection of Tumor Extracellular Vesicles via Plasmonic Droplet Microfluidics.

Pubblicato: 2026-05-22

ACS sensors

MediLens Indicizzato: 2026-05-23

PlasDroplex is a novel wash-free digital plasmonic assay designed for the early detection of tumor-derived extracellular vesicles (EVs) in cancer diagnostics. This method allows for the detection of EVs without the need for washing or multistep labeling, utilizing a coencapsulation of plasma with...

Leggi su PubMed

Impatto 3

Urine-Based Noninvasive Detection of Prostate Cancer Using Human Olfactory Receptor-Embedded Nanodiscs.

Pubblicato: 2026-05-22

ACS sensors

MediLens Indicizzato: 2026-05-23

This study presents a novel urine-based diagnostic platform for prostate cancer that utilizes a sensor array embedded with human olfactory receptors, combined with fluorescence sensing and machine learning. The platform aims to improve specificity in diagnosing prostate cancer, addressing the lim...

Leggi su PubMed

Tendenze della Ricerca Medica

Oncologia5 articoli

Baseline FDG PET/CT-Defined Axillary Burden Predicts Axillary Pathologic Complete Response After Neoadjuvant Therapy in Breast Cancer.

Fulvestrant versus capecitabine as maintenance therapy in hormone receptor-positive, HER2-negative metastatic breast cancer after first-line chemotherapy (FAMILY): a multicenter, open-label, randomized, phase 3 trial.

Aptamer Nanoswitch-Mediated Lock-Expose Mechanism Enables Highly Sensitive In Vitro Detection and Precise In Situ Membrane Imaging of HER2 Protein.

Wash-Free Digital Detection of Tumor Extracellular Vesicles via Plasmonic Droplet Microfluidics.

Urine-Based Noninvasive Detection of Prostate Cancer Using Human Olfactory Receptor-Embedded Nanodiscs.

Ricevi riassunti giornalieri personalizzati